Malaria in 1998: Advances in diagnosis, drugs and vaccine development

Current Opinion in Infectious Diseases

Volumn 11, Issue 5, 1998, Pages 519-530

  Heppner, D Gray ^a   Ballou, W Ripley ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTEETHER; ARTEMETHER; ARTEMISININ DERIVATIVE; ARTESUNATE; ATOVAQUONE; AZITHROMYCIN; CHLOROQUINE; DAPSONE; DIHYDROARTEMISININ DERIVATIVE; DOXYCYCLINE; FANSIDAR; HALOFANTRINE; HISTIDINE; LACTATE DEHYDROGENASE; LICOCHALCONE A; MALARIA VACCINE; MEFLOQUINE; PARASITE ANTIGEN; PHENANTHRENE DERIVATIVE; PRIMAQUINE; PROGUANIL; PYRONARIDINE; QUINIDINE; QUININE; SPOROZOITE VACCINE; TAFENOQUINE; THROMBOSPONDIN;

AUDITORY NERVOUS SYSTEM; BLOOD SMEAR; BRAIN STEM INJURY; CARDIOTOXICITY; COMA; CONVULSION; DEATH; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNIZATION; IMMUNOREACTIVITY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY DIAGNOSIS; MALARIA; MALARIA FALCIPARUM; MULTIDRUG RESISTANCE; NEUROLOGIC DISEASE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIMATE; PROPHYLAXIS; RECTAL DRUG ADMINISTRATION; REVIEW; SOUTHEAST ASIA; SUPPOSITORY; TABLET; TUBERCULOSIS;

EID: 0031791192     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199810000-00002     Document Type: Review

References (119)

1. Looareesuwan S, Buchachart K, Wilairatana P, Chalermrut K, Rattanapong Y, Amradee S, et al. Primaquine-tolerant vivax malaria in Thailand. Ann Trop Med Parasitol 1997; 91:939-943.
2. Smoak BL, DeFraites RF, Magil AJ, Kain KC, Wellde BT. Plasmodium vivax infections in US Army troops: failure of primaquine to prevent relapse in studies from Somalia. Am J Trop Med Hyg 1997; 56:231-234.
3. Doherty JF, Day JH, Warhurst DC, Chiodini PL. Treatment of Plasmodium vivax malaria - time for a change? Trans R Soc Trop Med Hyg 1997; 91:76.
4. World Health Organization. World malaria situation in 1994. Weekly Epidem Rec 1997; 72:269-276.
5. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 1997; 349:1436-1442.
6. Baud M, Bauchet E, Poilane I, Levacher S, Pourriat JL. Acute respiratory distress syndrome due to falciparum malaria in a pregnant woman. Intens Care Med 1997; 23:787-789.
7. Giacomini T, Axler O, Mouchet J, Lebrin P, Carlioz R, Paugam B, et al. Pitfalls in the diagnosis of airport malaria. Seven cases observed in the Paris area in 1994. Scand J Infect Dis 1997; 29:433-435.
8. Jenkin GA, Ritchie SA, Hanna JN, Brown GV. Airport malaria in Cairns. Med J Aust 1997; 166:307-308.
9. Anonymous. Probable locally acquired mosquito-transmitted Plasmodium vivax infection - Georgia, 1996. MMWR 1997; 46:264-267.
10. Wilton P. Malaria may be on move to 'tropical' Canada. Can Med Assoc J 1998; 158:160.
11. Lobel HI, Kozarsky PE. Update on prevention of malaria for travelers. JAMA 1997; 278:1767-1771.
12. White NJ. The treatment of malaria. N Engl J Med 1996; 335:800-806.
13. Kain KC, Harrington MA, Tennyson S, Keystone JS. Imported malaria. Prospective analysis of problems in diagnosis and management. Clin Infect Dis 1998; 27:142-149. A frank assessment of the need to educate physicians in industrialized countries to recognize, diagnose and treat malaria more effectively.
14. Kortepeter M, Brown JD. A review of 79 patients with malaria seen at a military hospital in Hawaii from 1979 to 1995. Mil Med 1998; 168:84-89.
15. Desakorn V, Silamur K, Ngus B, Sahassananda D, Chotivanich K, Suntharasamai P, et al. Semi-quantitative measurement of Plasmodium falciparum antigen PfHRP-2 in blood and plasma. Trans R Soc Trop Med Hyg 1997; 91:479-483. Whole blood PfHRP-2 concentrations correlated significantly with admission parasitemia. The authors suggest that semi-quantitative detection of PfHRP-2 by available commercial dipsticks might give useful prognostic information.
16. ® F-test compared with the polymerase chain reaction and microscopy for the diagnosis of Plasmodium falciparum malaria in travelers. Am J Trop Med Hyg 1997; 56:44-48.
17. ™ F test for malaria in patients with rheumatoid factor. Trans R Soc Trop Med Hyg 1998; 92:33-34.
18. Laferi H, Kandel K, Pichler H. False positive dipstick test for malaria. N Engl J Med 1997; 337:1635-1636.
19. ® test for rapid diagnosis of Plasmodium vivax and Plasmodium falciparum malaria. J Clin Microbiol 1998; 36:203-206. A laboratory evaluation of 202 field samples from patients using prototype pLDH-based MRDD versus light microscopy. The OpiMAL test detected 74 out of 79 P. vivax and 15 out of 17 P. falciparum parasitemias, a landmark publication of a simple test distinguishing the two leading causes of malaria.
20. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997; 41:1413-1422. An excellent review of parasitemia, parasite physiology, and response to treatment. The study advocates the use of a 48 h parasite reduction ratio as a prognosticator and guide to therapy. It reviews the important consideration of immunity and therapeutic response when comparing interventions in immune versus naive populations. It presents a cogent argument for the use of a treatment combination of any new, more slowly eliminated antimalarial drug with a rapidly acting antimalarial drug such as an oral artemisinin, especially if resistance to the new drug can develop through a simple point mutation.
21. Oduola AM, Omitowoju GO, Sowunmi A, Makler MT, Falade CO, Kyle DE, et al. Plasmodium falciparum: evaluation of lactate dehydrogenase in monitoring therapeutic responses to standard antimalarial drugs in Nigeria. Exp Parasitol 1997; 87:283-289.
22. Zalis MG, Pang L, Silveira MS, Milhous WK, Wirth DF. Characterization of Plasmodium falciparum isolated from the Amazon region of Brazil: evidence for quinine resistance. Am J Trop Med Hyg 1998; 58:630-637.
23. Wongsrichanalai C, Nguyen TD, Trieu NT, Wimonwattrawatee T, Sookto P, Heppner DG, Kawamoto F. In vitro susceptibility of Plasmodium falciparum isolates in Vietnam to artemisinin derivatives and other antimalarials. Acta Tropica 1997; 63:151-158.
24. Gay F, Bustos D, Traore B, Jardinel C, Southammavong M, Ciceron L, Danis MM. In vitro response of Plasmodium falciparum to atovaquone and correlation with other antimalarials: comparison between African and Asian strains. ASTM&H 1997; 56:315-317.
25. Olliaro P, Nevill C, LeBras J, Ringwald P, Mussano P, Garner P, Brasseur P. Systematic review of amodiaquine in uncomplicated malaria. Lancet 1996; 348:1196-1201.
26. Lell B, Doris L, NdJave M, Scott T, Kremsner PG. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998; 351:709-713.
27. Shanks GD, Gordon DM, Klotz FW, Aleman GM, Ollo AJ, Sadie D, Scott TR. Efficacy and safety of atovaquone/proguanil for suppressive prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis 1998; 27:494-499. This 10-week study demonstrated that low-or high-dose weekly atovaquone/ proguanil was well tolerated and 100% effective for the prevention of P. falciparum in malaria-experienced African adults.
28. Alencar FE, Cerutti Jr C, Durlacher RR, Boulos M, Alves FP, Milhous W, Pang LW. Atovaquone and proguanil for the treatment of malaria in Brazil. J Infect Dis 1997; 175:1544-1547.
29. Bloland PB, Kazembe PN, Watkins WM, Doumbo OK, Nwanyanwu OC, Ruebush TK. Malarone-donation programme in Africa. Lancet 1997; 350:1624-1625.
30. Ringwald P, Basco LK. Malarone-donation programme in Africa. Lancet 1998; 351:673-674.
31. Yeo AET, Edstein MD, Rieckmann KH. Antimalarial activity of the triple combination of proguanil, atovaquone and dapsone. Acta Tropica 1997; 67:207-214.
32. White NJ. Preventing antimalarial drug resistance through combinations. Drug Resist Updates 1998; 1:3-9. A wake up call.
33. Price RN, Nosten F, Luxemburger C, ter Kuile F, Paiphun L, Chongsuphajaisiddhi T, White NJ. The effects of artemisinin derivatives on malaria transmissibility. Lancet 1996; 347:1654-1658.
34. Andersen SL, Oloo AJ, Gordon DM, Ragama OB, Aleman GM, Berman JD, et al. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis 1998; 26:146-150.
35. Ohrt C, Richie TL, Widjala H, Shanks GD, Fitriadi J, Fryauff DJ, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126:963-972.
36. Gundersen SG, Rostrup M, von der Lippe E, Platou ES, Myrvang B, Edwards G. Halofantrine-associated ventricular fibrillation in a young woman with no predisposing QTc prolongation. Scand J Infect Dis 1997; 29:207-208.
37. Touze JE, Fourcade L, Heno P, Deharo JC. Is halofantrine still advisable in malaria attacks? Ann Trop Med Parasitol 1997; 91:867-873.
38. Touze JE, Perret JL, Nicolas X, Fourcade L, Bernard J, Keundjian A, et al. Efficacy of low-dose halofantrine for second treatment of uncomplicated falciparum malaria. Lancet 1997; 349:255-256.
39. Fryauff DJ, Baird JK, Basri H, Widy I, Purnomo , Bangs MJ, et al. Halofantrine and primaqune for radical cure of malaria in Irian Jaya, Indonesia. Ann Trop Med Parasitol 1997; 91:7-16.
40. Croft AMJ, Clayton TC, World MJ. Side effects of mefloquine prophylaxis for malaria: an independent randomized trial. Trans R Soc Trop Med Hyg 1997; 1:159-203.
41. Croft A, Garner P. Mefloquine to prevent malaria: a systematic review of trials. BMJ 1997; 315:1412-1416.
42. Bradley DJ, Warhurst DC. Guidelines for the prevention of malaria in travellers from the United Kingdom. Communicable Dis Rev 1997; 7:R138-R151.
43. Schlagenhauf P, Steffen R, Johnson R, Popp K, Tschopp A, Letz R, Crevoisier C. Tolerance of mefloquine by Swissair trainee pilots. Am J Trop Med Hyg 1997; 56:235-240.
44. Ringwald P, Bickii J, Basco LK. Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children. Clin Infect Dis 1998; 26:946-953.
45. Brueckner RP, Lasseter KC, Lin ET, Schuster BG. First-in-humans safety and pharmacokinetics of WR238605, a new antimalarial. Am J Trop Med Hyg 1998; 58:645-649.
46. Genovese RF, Newman DB, Petras JM, Brewer TG. Behavioral and neural toxicity of arteether in rats. Pharmacol Biochem Behav 1998; 60:1-10. This study demonstrates brainstrem pathology in rats after only 3 days of arteether (25 mg/kg).
47. Genovese RF, Newman DB, Li Q, Peggins JO, Brewer TG. Dose-dependent brainstem neuropathology following repeated arteether administration in rats. Brain Res Bull 1998; 45:199-202. Brain lesions at several dose multiples of human doses raise the specter of human neurotoxicity in cases: (1) of inadvertent overdosing; (2) in which parenteral oil-soluble artemisinins are given 'to effect', as might happen in severe malaria; or (3) of unknown cumulative effect of multiple treatment doses. These results in rats emphasize the need for regulatory level studies in primate models.
48. Kamchonwongpaisin S, McKeever P, Hossler P, Ziffer H, Meshnick SR. Artemisinin neurotoxicity: neuropathology in rats and mechanistic studies in vitro. Am J Trop Med Hyg 1997; 56:7-12.
49. Petras JM, Kyle DE, Gettyacamin M, Young GD, Bauman RA, Webster HK, et al. Arteether: risks of two-week administration in Macaca mulatta. Am J Trop Med Hyg 1997; 56:390-396.
50. Van Hensbroek M, Onyiorah E, Jaffar S, Schneider G, Palmer A, Frenkel J, et al. A trial of artemether or quinine in children with cerebral malaria. N Engl J Med 1996; 335:69-75.
51. Hien T, Day N, Phu N, Mai N, Chan T, Loc P, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335:76-83.
52. Miller LG, Panosian CB. Artesunate and cerebellar dysfunction in falciparum malaria. N Engl J Med 1997; 337:792-793.
53. Looareesuwan S, Wilairatana P, Viravan C, Vanijanonta S, Pitisuttithum P, Kyle DE. Open randomized trail of oral artemether alone and a sequential combination with mefloquine for acute uncomplicated falciparum malaria. Am J Trop Med Hyg 1997; 56:613-617.
54. Sabchaeron A, Attanath P, Chantavanich P, Phanuaksook P, Prarinyanupharb V, Poonpanich Y, et al. Comparative clinical trial of artesunate suppositories and oral artesunate in combination with mefloquine in the treatment of acute falciparum malaria. Am J Trop Med Hyg 1998; 58:11-16.
55. Looareesuwan S, Wilairatana P, Molunto W, Chalermrut K, Olliaro P, Andrial M. A comparative clinical trial of sequential treatments of severe malaria with artesunate suppository followed by mefloquine in Thailand. Am J Trop Med Hyg 1997; 57:348-353.
56. Price RN, Nosten F, Luxemburger C, van Vugt M, Phaipun L, Chongsuphajaisiddhi T, White NJ. Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. Am J Trop Med Hyg 1997; 91:574-577.
57. van Vugt M, Brockman A, Gemperli B, Luxemburger C, Gathmann I. Royce C, et al. Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother 1998; 42:135-139. The first study outside China to test a drug combination (AB) against the most resistant falciparum strains. Significantly fewer side-effects (including fewer neurological side-effects) were seen in the AB-treated group. Trials continue of higher dose and longer duration regimens. The relatively low population immunity and the highly resistant falciparum strains endemic here suggest that the efficacy results from these ongoing studies on the Thai-Burmese border will be applicable world-wide.
58. Le NN, de Vries PJ, Le TD, Bich L, Ho PL, Tran NH , ef al. Single-dose artemisinin-mefloquine versus mefloquine alone for uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 1997; 91:191-194.
59. von Seidlein L, Bolang K, Jone P, Jaffar S, Pinder M, Obaro S , et al. A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children. Am J Trop Med Hyg 1998; 58:638-645. Artemether/benflumetol (CGP56697, coartemether) was safe, well tolerated, and demonstrated rapid fever and parasite clearance times. Most importanly, 2 weeks after therapy, no children treated with CGP56697 had gametocytes versus 29% of those treated with pyrimethamine/sulfadoxine.
60. von Seidlein L, Jaffar S, Pinder M, Haywood M, Snounou G, Gemperli B, et al. Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. J Infect Dis 1997; 176:113-116.
61. Roberts F, Roberts CW, Johnson JJ, Kyle DE, Krell T, Coggins JR, et al. Evidence for the shikimate pathway in apicomplexan parasites. Nature 1998; 393:801-805. The discovery of biochemical, genetic and chemotherapeutic evidence for a shikamate pathway in P. falciparurm that opens a new anti-parasitic vista for drug development.
62. Chen M, Christensen SB, Zhai L, Rasmussen MH, Theander TG, Frokjaer S, et al. The novel oxygenated chalcone, 2,4,-dimethoxy-4′-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelli in vivo. J Infect Dis 1997; 176:1327-1333.
63. Lin AJ, Zikry AB, Kyle DE. Antimalarial activity of new dihydroartemisinin derivatives 7,4-(p-substituted phenyl)-4(R or S)-[10(alpha or beta)-dihydroartemisininoxy]butyric acids. J Med Chem 1997; 40:1396-1440.
64. Barker RH, Metelev V, Coakley A, Zamecnik P. Plasmodium falciparum: effect of chemical structure on efficacy and specificity of antisense olignucleotides against malaria in vitro. Exp Parasitol 1998; 88:51-59.
65. Rosenthal PJ. Proteases of malaria parasites: new targets for chemotherapy. Emerg Infect Dis 1998; 4:49-57.
66. Bottius E, Bakhsis N, Scherf A. Plasmodium falciparum telomerase: de novo telomere addition to telomeric and nontelomeric sequences and role in chromosome healing. Mol Cell Biol 1998; 18:919-925.
67. Menard R, Sultan AA, Cortes C, Altszuler R, Vandijk MR, Janse CJ, et al. Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes. Nature 1997; 385:336-340.
68. Ying P, Shakibaei M, Patankar MS, Clavijo P, Beavis RC, Clark GF, Frevert U. The malaria Circumsporozoite protein: interaction of the conserved regions I and II-plus with heparin-like oligosaccharides in heparan sulfate. Exp Parasitol 1997; 85:168-182.
69. Rodrigues EG, Zavala F, Eichinger D, Wilson JM,] Tsuji M. Single immunizing dose of recombinant adenovirus efficiently induces CD8(+) cell-mediated protective immunity against malaria. J Immunol 1997; 158:1268-1274.
70. Sultan AA, Thathy V, Frevert U, Robson KJH, Crisanti A, Nussenzweig V, et al. TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites. Cell 1997; 90:511-522.
71. Robson KJ, Dolo A, Hackford IR, Doumbo O, Richards MB, Keita MM, et al. Natural polymorphism in the thrombospondin-related adhesive protein of Plasmodium falciparum. Am J Trop Med Hyg 1998; 58:81-89.
72. Charoenvit Y, Fallarme V, Rogers WO, Sacci JB, Kaur M, Aguiar JC, et al. Development of two monoclonal antibodies against Plasmodium falciparum sporozoite surface protein 2 and mapping of B-cell epitopes. Infect Immun 1997; 65:3430-3437.
73. Kappe SHI, Noe AR, Fraser TS, Blair PL, Adams JH. A family of chimeric erythrocyte binding proteins of malaria parasites. Proc Natl Acad Sci U S A 1998; 95:1230-1235.
74. Okenu DM, Malhotra P, Lalitha PV, Chitnis CE, Chauhan VS. Cloning and sequence analysis of a gene encoding an erythrocyte binding protein from Plasmodium cynomolgi. Mol Biochem Parasitol 1997; 89:301-306.
75. Daugherty JR, Murphy CI, Dorosrichert LA, Barbosa A, Kashala LO, Ballou WR, et al. Baculovirus-mediated expression of Plasmodium falciparum erythrocyte binding antigen 175 polypeptides and their recognition by human antibodies. Infect Immun 1997; 65:3631-3637.
76. Stowers A, Taylor D, Prescott N, Cheng Q, Cooper J, Saul A. Assessment of the humoral immune response against Plasmodium falciparum rhoptry-associated proteins 1 and 2. Infect Immun 1997; 65:2329-2338.
77. Fonjungo PN, Stuber D, McBride JS. Antigenicity of recombinant proteins derived from rhoptry-associated protein 1 of Plasmodium falciparum. Infect Immun 1998; 66:1037-1044.
78. Tian JH, Kumar S, Kaslow DC, Miller LH. Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii. Infect Immun 1997; 65:3032-3036.
79. Renia L, Ling IT, Marussig M, Miltgen F, Holder AA, Mazier D. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge. Infect Immun 1997; 65:4419-4423.
80. Egan A, Waterfall M, Pinder M, Holder A, Riley E. Characterization of human T-and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds. Infect Immun 1997; 65:3024-3031.
81. Hirunpetcharat C, Tian JH, Kaslow DC, Vanrooijen N, Kumar S, Berzofsky JA, et al. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1(19)) of Plasmodium yoelii expressed in Saccharomyces cerevisiae - correlation of protection with antigen-specific antibody titer, but not with effector CD4(+) T cells. J Immunol 1997; 159:3400-3411.
82. Branch OH, Udhayakumar V, Hightower AW, Oloo AJ, Hawley WA, Nahlen BL, et al. A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants; associations with febrile illness, parasitemia, and anemia. Am J Trop Med Hyg 1998; 58:211-219. Further evidence in support of C-terminal MSP-1 vaccine strategies.
83. Patino JA, Holder AA, McBride JS, Blackman MJ. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J Exp Med 1997; 186:1689-1699.
84. Rzepczyk CM, Hale K, Woodroffe N, Bobogare A, Csurhes P, Ishii A, Ferrante A. Humoral Immune responses of Solomon islanders to the merozoite surface antigen 2 of Plasmodium falciparum show pronounced skewing towards antibodies of the immunoglobulin IgG3 subclass. Infect Immun 1997; 65:1098-1100. The unexpected distribution of IgG subclass responses to MSP-2 support the hypothesis that this antigen may be an important target for ADCl-mediated killing of asexual stage parasites.
85. Ferrante A, Rzepczyk CM. A typical IgG subclass antibody responses to Plasmodium falciparum asexual stage antigens. Parasitol Today 1997; 13:145-148. This study presents a possible clue to the basis of short-lived persistance of clinical immunity.
86. Pye D, Vandenberg KL, Dyer SL, Irving DO, Goss NH, Woodrow GC, et al. Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. Vaccine 1997; 15:1017-1023.
87. McColl DJ, Anders RF. Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3). Mol Biochem Parasitol 1997; 90:21-31.
88. Marshall VM, Silva A, Foley M, Cranmer S, Wang L, McColl DJ, et al. A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain. Infect Immun 1997; 65:4460-4467.
89. Theisen M, Soe S, Oeuvray C, Thomas AW, Vuust J, Danielsen S, et al. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect Immun 1998; 66:11-17.
90. Bull PC, Lowe BS, Kortok M, Molyneux CS, Newbold CI, Marsh K. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nature Medicine 1998; 4:358-360.
91. Chen Q, Barragan A, Fernandez V, Sundstrom A, Schlichtherle M, Sahlen A, Carlson J, Datta S, Wahlgren M. Identification of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP-1) as the resetting ligand of the malaria parasite P. falciparum. J Exp Med 1998; 187:15-23.
92. Reeder JC, Davern KM, Baird JK, Rogerson SJ, Brown GV. The age-specific prevalence of Plasmodium falciparum in migrants to Irian Jaya is not attributable to agglutinating antibody repertoire. Acta Trop (Basel) 1997; 65:163-173.
93. Lescanf C, Fandeur T, Moralesbetoulle ME, Mercereau-Puijalon O. Plasmodium falciparum: altered expression of erythrocyte membrane-associated antigens during antigenic variation. Exp Parasitol 1997; 85:135-148.
94. Baruch DI, Ma XC, Singh HB, Bi XH, Pasloske BL, Howard RJ. Identification of a region of PfEMP-1 that mediates adherence of Plasmodium falciparum infected erythrocytes to CD36: conserved function with variant sequence. Blood 1997; 90:3766-3775.
95. Duffy PE, Kaslow DC. A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect Immun 1997; 65:1109-1113. This paper demonstrates that antibodies against the two leading candidate antigens for a human transmission blocking vaccine act synergistically to interrupt sporogony.
96. Sidjanski S, Vanderberg JP. Delayed migration of Plasmodium sporozoites from the mosquito bite site to the blood. Am J Trop Med Hyg 1997; 57:426-429.
97. + T lymphocytes producing IL-4 in response to antigens on Plasmodium falciparum erythrocytes: an in vitro correlate of protective immunity induced with attenuated Plasmodium falciparum sporozoites. Cell Immunol 1997; 180:143-152.
98. Scheller LF, Green SJ, Azad AF. Inhibition of nitric oxide interrupts the accumulation of CD8(+) T cells surrounding Plasmodium berghei-infected hepatocytes. Infect Immun 1997; 65:3882-3888.
99. Plebanski M, Aidoo M, Whittle HC, Hill AVS. Precursor frequency analysis of cytotoxic T lymphocytes to pre-erythrocytic antigens of Plasmodium falciparum in West Africa. J Immunol 1997; 158:2849-2855.
100. + CTLs. It may have important implications for vaccine strategies in which the focus is CTL induction.
101. Sarthou JL, Angel G, Aribot G, Rogier C, Dieye A, Balde AT, et al. Prognostic value of anti-Plasmodium falciparum specific immunoglobulin G3, cytokines, and their soluble receptors in West African patients with severe malaria. Infect Immun 1997; 65:3271-3276.
102. Druilhe P, Sabchareon A, Bouharountayoun H, Oeuvray C, Perignon JL. In vivo veritas: lessons from immunoglobulin-transfer experiments in malaria patients. Ann Trop Med Parasitol 1997; 91;S37-S53. A fascinating review and presentation of the ADCI hypothesis.
103. Druilhe P, Perignon JL. A hypothesis about the chronicity of malaria infection. Parasitol Today 1997; 13:353-357. A further presentation of the ADCI hypothesis.
104. Golenda CF, Li J, Rosenberg R. Continuous in vitro propagation of the malaria parasite Plasmodium vivax. Proc Natl Acad Sci USA 1997; 94:6786-6791. An important breakthrough in methods for culturing P. vivax.
105. Urdaneta M, Prata A, Struchiner CJ, Tosta CE, Tauil P, Boulos M, Evaluation of SPf66 malaria vaccine efficacy in Brazil. Am J Trop Med Hyg 1998; 58:378-385.
106. Bojang KA, Obaro SK, Leach A, D'Alessandro U, Bennett S, Metzger W, et al. Follow-up of Gambian children recruited to a pilot safety and immunogenicity study of the malaria vaccine SPf66. Parasite Immunol 1997; 19:579-581.
107. Beck HP, Felger I, Huber W, Steiger S, Smith T, Weiss N, et al. Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the phase III trial of the malaria vaccine SPf66. J Infect Dis 1997; 175:921-926.
108. Migasena S, Heppner DG, Kyle DE, Chongsuphajalsiddhi T, Gordon DM, Suntharasamal P, et al. SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in Thailand. Acta Trop (Basel) 1997; 67:215-227.
109. Nosten F, Luxemburger C, Kyle DE, Gordon DM, Ballou WR, Sadoff JC, et al. Phase I trial of the SPf66 malaria vaccine trial in a malaria-experienced population in southeast Asia. Am J Trop Med Hyg 1997; 56:526-532.
110. al-Yaman F, Genton B, Taraika J, Alpers MP. Naturally acquired cellular immune responses to the synthetic malarial peptide SPf66 in children in Papua New Guinea. Trans R Soc Trop Med Hyg 1997; 91:709-712.
111. Ockenhouse CF, Sun P, Lanar DE, Wellde BT, Hall BT, Kester K, et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998; 177:1664-1673.
112. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997; 336:86-91. This study describes vaccine protection of six out of seven malaria-naive volunteers against homologous sporozoite challenge. Earlier trials with the same antigen had failed to protect. Success was attributed to the formulation of the RTS,S antigen with a potent adjuvant system containing MPL and QS21 in an oil-in-water emulsion.
113. Greenwood BM. What can be expected from malaria vaccines? Ann Trop Med Parasitol 1997; 91:S9-S13. A thoughful overview of malaria vaccines and their impact.
114. Cheng Q, Lawrence G, Reed C, Stowers A, Ranford-Cartwright L, Creasey A, et al. Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am J Trop Med Hyg 1997; 57:495-500.
115. Hurtado S, Salas ML, Romero JF, Zapata JC, Ortiz H, Arevaloherrera M, Herrera S. Regular production of infective sporozoites of Plasmodium falciparum and P. vivax in laboratory-bred Anopheles albimanus. Ann Trop Med Parasitol 1997; 91:49-60.
116. Collins WE, Sullivan JS, Morris CL, Galland GG, Richardson BB, Roberts JM. The Malayan IV strain of Plasmodium falciparum in Aotus monkeys. Am J Trop Med Hyg 1997; 56:49-56.
117. Perera KL, Handunnetti SM, Holm I, Longacre S, Mendis K. Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria. Infect Immun 1998; 66:1500-1506.
118. Gramzinski RA, Mans DC, Doolan D, Charoenvit Y, Obaldia N, Rossan R, et al. Malaria DNA vaccines in Aotus monkeys. Vaccine 1997; 15:913-915. Route-dependent immunogenicity in non-human primates reveals the lack of predictability of murine models. Human studies are likely to be required to establish the optimal dose, routes, and timing of DNA immunization.
119. Hoffman SL, Doolan DL, Sedegah M, Aguiar JC, Wang R, Malik A, et al. Strategy for development of a pre-erythrocytic Plasmodium falciparum DNA vaccine for human use. Vaccine 1997; 15:842-845. A review laying out the rationale for the development of multigene DNA vaccine targeting multiple stages of the life cycle.